Agenus Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
113.28 M |
Public Float |
79.21 M |
Agenus Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.8 |
Market Cap |
$361.16 M |
Shares Outstanding |
134.26 M |
Public Float |
98.67 M |
Address |
3 Forbes Road Lexington Massachusetts 02421 United States |
Employees | - |
Website | http://www.agenusbio.com |
Updated | 07/08/2019 |
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, Next-gen CTLA-A, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. |